New CAR-T therapy targets different protein in Hard-to-Treat blood cancer
NCT ID NCT06185751
Summary
This early-stage trial is testing a new CAR-T cell therapy called WS-CART-CS1 for people with multiple myeloma that has returned or stopped responding to at least three previous treatments. The study aims to find the safest dose and see if this therapy, which targets a protein called CS1 on cancer cells, can help control the disease. Researchers will enroll about 25 patients to monitor side effects and initial effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.